NCT05022693View on ClinicalTrials.gov

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

December 21, 2021

Study Completion Date

December 21, 2021

Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

BIO89-100

Subcutaneous Injections

Trial Locations (1)

85224

89bio Clinical Study Site, Chandler

Sponsors

Lead Sponsor

89bio, Inc.
All Listed Sponsors
lead

89bio, Inc.

INDUSTRY

NCT05022693 - PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis | Biotech Hunter | Biotech Hunter